agatolimod

Small moleculeexperimental

Agatolimod is a CpG Oligodeoxynucleotide which acts as a toll-like receptor 9 agonist. Agatolimod stimulates the immune system and has been tested for prevention and treatment of cancer, infectious diseases, allergies, and asthma. — Wikipedia

Clinical trial activity

41 trials · 26 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2001 (NCT00031278)

Timeline

2000s

Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Jan 1, 2005
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Toll-like receptor 9AGONIST
TLR9 agonist
Targets TLR9, thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens
- Toll-like receptor 9 (TLR9) ↗

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O

Mol. weight: 7698.32 g/mol
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

agatolimod
agatolimod
agatolimod sodium
agatolimod sodium
cp-7909
cpg 2006
cpg7907
cpg 7907
cpg-7907
cpg7909
cpg7909
cpg7909
cpg 7909
cpg 7909
cpg 7909
cpg-7909
cpg-7909
cpg-7909
cpg8916
cpg 8916
cpg-8916
cpg8954
cpg 8954
cpg-8954
pf03512676
pf03512676
pf03512676
pf3512676
pf3512676
pf3512676
pf 3512676
pf-3512676
pf-3512676
pf-3512676
pf-3512676
promune

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01164514	Phase 1	Nov 1, 2011	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01351948	Phase 1	Jun 1, 2011	National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford
NCT00984763	Phase 1/Phase 2 (Phase 2)	Jan 1, 2010	National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford
NCT00490529	Phase 2	Aug 1, 2009	National Institutes of Health (NIH), Stanford University
NCT00889616	Phase 1	Apr 23, 2009	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00824733	Phase 2	Feb 1, 2009	Ohio State University, Pfizer
NCT00880581	Phase 2	Jan 1, 2009	Pfizer, Stanford University
NCT00471471	Phase 1	Oct 1, 2008	National Cancer Institute (NCI), University of Pittsburgh
NCT00740090	Phase 1	Aug 11, 2008	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00562939	Phase 1/Phase 2 (Phase 2)	Jan 1, 2008	Aarhus University
NCT00559975	Phase 1	Oct 1, 2007	Novartis
NCT00471159	Phase 2	Aug 1, 2007	Pfizer
NCT00427167	Phase 1	Jan 23, 2007	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00414336	Phase 1	Dec 15, 2006	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
NCT00722839	Phase 1	Dec 1, 2006	City of Hope National Medical Center, National Cancer Institute (NCI)
NCT00669292	Phase 1/Phase 2 (Phase 2)	Nov 1, 2006	University of Tokyo, Wakayama Medical University
NCT00321308	Phase 2	Sep 1, 2006	Pfizer
NCT00321815	Phase 2	Aug 1, 2006	Pfizer
NCT00320658	Phase 1	Mar 1, 2006	Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
NCT00299728	Phase 1	Mar 1, 2006	Columbia University, Ludwig Institute for Cancer Research, New York University

Showing 20 of 41 trials

Page 1 / 3

Organizations

Research & Development (26)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	16	13	3	2001
National Institute of Allergy and Infectious Diseases (NIAID)	Government	10	8	2	2004
National Cancer Institute (NCI)	Government	6	0	2	2002
Ludwig Institute for Cancer Research	Academic/Hospital	4	3	2	2004
Stanford University	Academic/Hospital	4	4	1	2004
National Institutes of Health (NIH)	Government	3	0	2	2005
Mayo Clinic	Academic/Hospital	2	1	2	2004
University of Oxford	Academic/Hospital	2	2	2	2010
Aarhus University	Academic/Hospital	1	1	1	2008
American Society of Clinical Oncology	Academic/Hospital	1	0	1	2004
Case Western Reserve University	Academic/Hospital	1	0	1	2004
City of Hope National Medical Center	Academic/Hospital	1	1	1	2006
Columbia University	Academic/Hospital	1	0	1	2006
Harvard University	Academic/Hospital	1	0	1	2001
Johns Hopkins University	Academic/Hospital	1	0	1	2006
Lymphoma Research Foundation	Academic/Hospital	1	0	1	2004
New York University	Academic/Hospital	1	0	1	2006
Novartis	For profit	1	1	1	2007
Ohio State University	Academic/Hospital	1	1	1	2009
University of California, Los Angeles	Academic/Hospital	1	1	1	2002

26 organizations

Page 1 / 2